Determination of homogentisic acid in urine for diagnosis of alcaptonuria: Capillary electrophoretic method optimization using experimental design

A ratiometric molecular imprinted electrochemiluminescence sensor based on enhanced luminescence of CdSe@ZnS quantum dots by MXene@NaAsc for detecting uric acid

An unlabeled ratiometric molecular imprinted electrochemiluminescence sensor was developed for the determination of trace uric acid, based on MXene@NaAsc nanocomposites, CdSe@ZnS quantum dots and molecularly imprinted polymer composites modified glass carbon electrode. MXene@NaAsc stably enhanced the electron transfer and improved electrochemiluminescence intensity by acting as a base platform and signal amplifier for CdSe@ZnS quantum dots. Specific molecular imprinting cavities based on electropolymerization with o-phenylenediamine were formed to specifically identify uric acid. Combining the good sensitivity of electrochemiluminescence and the excellent selectivity of molecularly imprinted polymer, the ratio of optical signal and electrical signal was used as a comprehensive signal to achieve the detection of uric acid. Based on this, uric acid was detected in the range from 1 × 10-10 to 1 × 10-4 mol/L with the LOD of 18.13 pmol/L (S/N = 3). The developed sensor with easy preparation, great selectivity and excellent sensitivity could successfully detect uric acid in human serum.

Highly sensitive rapid determination of orotic acid in urine samples using a field-amplified sample stacking approach in capillary electrophoresis coupled with contactless conductivity detection

Orotic aciduria is a severe, hereditary, life-threatening condition, particularly in newborns. An increased orotic acid (OA) content in urine may be a strong indicator of this condition. In this study, we developed a rapid, simple, highly sensitive diagnostic method for use in monitoring the OA levels in urine samples, which were successfully determined using capillary electrophoresis combined with capacitively coupled contactless conductivity detection (CE-C4D). A straightforward analysis with an increased sensitivity towards OA and an analysis time of approximately 5 min were realized, and the limit of detection of the developed method was 0.014 mg/L in aqueous solution. The optimized composition of the separation electrolyte was 20 mM 2-(N-morpholino)ethanesulfonic acid/histidine with 0.1 mM cetyltrimethylammonium bromide at a pH of 6.5. The sensitivity of the developed method was significantly increased using a sample stacking approach with a 10% acetonitrile (v/v) plug solution. The method was validated, and satisfactory recoveries of 80.0-92.3% were obtained. The amounts of OA in five urine samples were successfully determined.

Alkaptonuria – Many questions answered, further challenges beckon

Alkaptonuria is an iconic rare inherited inborn error of metabolism affecting the tyrosine metabolic pathway, resulting in the accumulation of homogentisic acid in the circulation, and significant excretion in urine. Dating as far back as 1500 BC in the Egyptian mummy Harwa, homogentisic acid was shown to be central to the pathophysiology of alkaptonuria through its deposition in collagenous tissues in a process termed ochronosis. Clinical manifestations occurring as a consequence of this are typically observed from the third decade of life, are lifelong and significantly affect the quality of life. In large supportive and palliative treatment measures are available to patients, including analgesia, physiotherapy and joint replacement. Studying the natural history of alkaptonuria, in a murine model and human subjects, has provided key insights into the biochemical and molecular mechanisms underlying the pathophysiology associated with the disease, and has enabled a better understanding of the common disease osteoarthritis. In the last decade, a major focus has been on an unlicensed disease-modifying therapy called nitisinone. This has been shown to be highly efficacious in reducing homogentisic acid, and it is hoped this will halt ochronosis, thus limiting the clinical complications associated with the disease. A well-documented metabolic consequence of nitisinone therapy is hypertyrosinaemia, the clinical implications of which are uncertain. Recent metabolomic studies have helped understand the wider metabolic consequences of nitisinone therapy.